Biogen Inc. $BIIB Shares Sold by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund decreased its position in Biogen Inc. (NASDAQ:BIIB) by 22.3% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 83,120 shares of the biotechnology company’s stock after selling 23,801 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in Biogen were worth $11,643,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BIIB. Elevation Point Wealth Partners LLC purchased a new position in shares of Biogen during the second quarter valued at approximately $25,000. Rothschild Investment LLC raised its holdings in Biogen by 64.7% in the 2nd quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 88 shares during the last quarter. True Wealth Design LLC raised its holdings in Biogen by 62.9% in the 3rd quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 90 shares during the last quarter. NewSquare Capital LLC lifted its stake in shares of Biogen by 134.6% during the 2nd quarter. NewSquare Capital LLC now owns 244 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 140 shares during the period. Finally, WFA of San Diego LLC acquired a new stake in shares of Biogen during the second quarter worth $32,000. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms recently commented on BIIB. Piper Sandler upped their target price on Biogen from $157.00 to $177.00 and gave the company a “neutral” rating in a research note on Monday. TD Cowen boosted their target price on shares of Biogen from $175.00 to $215.00 and gave the company a “buy” rating in a report on Monday. Truist Financial boosted their target price on Biogen from $190.00 to $193.00 and gave the stock a “hold” rating in a report on Monday. Guggenheim raised their price target on shares of Biogen from $185.00 to $246.00 and gave the company a “buy” rating in a report on Monday. Finally, HSBC reaffirmed a “reduce” rating and set a $143.00 price target (down from $144.00) on shares of Biogen in a research report on Wednesday, December 10th. Twelve investment analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $205.84.

Insider Buying and Selling at Biogen

In related news, insider Priya Singhal sold 2,660 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the sale, the insider directly owned 8,043 shares of the company’s stock, valued at approximately $1,607,232.69. This represents a 24.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.18% of the company’s stock.

Biogen Trading Up 2.2%

NASDAQ:BIIB opened at $195.50 on Friday. The stock has a market cap of $28.69 billion, a price-to-earnings ratio of 22.19, a price-to-earnings-growth ratio of 1.52 and a beta of 0.16. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.03 and a current ratio of 2.68. The business’s 50-day simple moving average is $177.92 and its 200 day simple moving average is $158.38. Biogen Inc. has a one year low of $110.04 and a one year high of $202.41.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.61 by $0.38. The business had revenue of $2.28 billion during the quarter, compared to analyst estimates of $2.21 billion. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The business’s revenue was down 7.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.44 earnings per share. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, sell-side analysts predict that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

Biogen News Roundup

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q4 beat and raised FY‑2026 guidance — Biogen reported EPS and revenue above consensus and set FY‑2026 EPS guidance of $15.25–$16.25, which underpins improved earnings visibility and has been a major catalyst for analyst upgrades. Article Title
• Positive Sentiment: Leqembi subcutaneous BLA gets priority review — The subcutaneous formulation (lecanemab) received a priority review designation, which could expand commercial reach and margins if approved. This boosts upside to the Alzheimer’s franchise over the medium term. Article Title
• Positive Sentiment: Analyst upgrades and higher price targets — Several firms lifted targets (Mizuho to $236, Citi, RBC, Canaccord and others raised targets), supporting further upside expectations and trading interest. Article Title
• Positive Sentiment: Institutional accumulation — Major holders (Vanguard, State Street, Geode, Norges Bank, Invesco) either added or maintain large stakes, indicating continued institutional conviction and providing bid support.
• Neutral Sentiment: Board chair transition — Caroline Dorsa is retiring and Dr. Maria C. Freire was elected chair. Governance change reduces uncertainty about succession but is unlikely to be an immediate earnings driver. Article Title
• Neutral Sentiment: Short‑interest data appears unreliable — Published short‑interest entries show zero shares / NaN changes and are internally inconsistent; there’s no clear sign of short‑covering driving today’s move.
• Negative Sentiment: Insider sale — Director/officer Priya Singhal sold 2,660 shares recently (filing shows sales around the $180–$200 range). Insider selling can raise short‑term concern about timing or valuation. Article Title
• Negative Sentiment: Ongoing franchise pressure and execution risk — Analysts and commentary note MS franchise pressures and execution risk around scaling Leqembi access/commercialization, which could cap upside if execution slips. Article Title

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.